中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2018, Vol. 47 ›› Issue (4): 333-337.doi: 10.12007/j.issn.0258-4646.2018.04.010

• 论著 • 上一篇    下一篇

英夫利西单抗治疗中重度活动性克罗恩病的疗效及安全性

兰雨桐1, 刘威宇1,2, 邢俊伟1,3, 来爽1, 杨慧珊1, 李虹1, 邓秋萍1, 刘维新1   

  1. 1. 中国医科大学附属第一医院消化内科, 沈阳 110001;
    2. 辽宁省人民医院消化二科, 沈阳 110013;
    3. 营口市中心医院消化内科, 辽宁 营口 115003
  • 收稿日期:2017-12-21 出版日期:2018-04-30 发布日期:2018-04-10
  • 通讯作者: 刘维新 E-mail:weixinliu@yahoo.com
  • 作者简介:兰雨桐(1993-),女,硕士研究生.
  • 基金资助:
    辽宁省科学技术计划(2013225303)

Efficacy and Safety of Infliximab in Treating Patients with Severe Active Crohn's Disease

LAN Yutong1, LIU Weiyu1,2, XING Junwei1,3, LAI Shuang1, YANG Huishan1, LI Hong1, DENG Qiuping1, LIU Weixin1   

  1. 1. Department of Digestive Diseases, The First Hospital, China Medical University, Shenyang 110001, China;
    2. The Second Department of Digestive Diseases, The People's Hospital of Liaoning Province, Shenyang 110013, China;
    3. Department of Digestive Diseases, Yingkou Central Hospital, Yingkou 115003, China
  • Received:2017-12-21 Online:2018-04-30 Published:2018-04-10

摘要: 目的 观察英夫利西单抗(IFX)治疗克罗恩病(CD)的疗效与安全性。方法 回顾性分析42例传统药物疗效差或再次复发的CD患者应用IFX治疗的疗效,评估疾病活动度、血生化指标、并发症、结肠镜结果及药物的安全性。结果 42例患者经IFX治疗14周,39例达到临床有效,34例达到临床缓解,CD活动指数(CDAI)评分、C反应蛋白(CRP)、血沉、血小板计数均明显下降(P < 0.05)。21例患者经IFX治疗38周,CDAI评分、CRP、血沉、血小板计数明显下降(P<0.05),而血红蛋白、白蛋白明显升高(P < 0.05)。7例肛瘘均有不同程度缓解。不良反应仅5次。结论 IFX对经传统药物治疗效果不佳或再次复发的CD患者效果良好,近期不良反应率较低,总体安全。

关键词: 英夫利西单抗, 克罗恩病, 疗效, 安全性

Abstract: Objective To observe the efficacy and safety of infliximab (IFX) for the treatment of patients with Crohn's disease (CD). Methods We retrospectively analyzed the efficacy of IFX therapy in 42 patients with active CD who had shown no obvious improvement or had shown relapse after treatment with traditional medicine. The change in disease activity,blood biochemical indices,complications,and colonoscopic examination results were compared and analyzed. Results Among the 42 patients who received IFX therapy, 39 achieved clinical efficacy and 34 achieved clinical remission. In these 42 patients,the CD activity index score,C-reactive protein, erythrocyte sedimentation rate,and platelet count were significantly decreased (P < 0.05). In 21 patients receiving IFX treatment for 38 weeks,the CD activity index score,C-reactive protein,erythrocyte sedimentation rate,and platelet count were significantly decreased,and the hemoglobin and albumin levels were significantly increased (P < 0.05). Seven patients with an anal fistula showed varying degrees of symptom relief. Adverse reactions occurred in only 5 patients during the treatment. Conclusion IFX is effective in patients with a poor response to or relapse with the use of traditional medicine. The incidence of adverse reactions is low and overall,IFX is a safe drug.

Key words: infliximab, Crohn's disease, treatment, safety

中图分类号: 

  • R574
[1] DING NS,HART A,DE CRUZ P. Systematic review:predicting and optimising response to anti-TNF therapy in Crohn's disease-algorithm for practical management[J]. Aliment Pharmacol Ther,2016,43(1):30-51. DOI:10.1111/apt.13445.
[2] NICHOLLS S,STEPHENS S,BRAEGGER CP,et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhea[J]. J Clin Pathol,1993,46(8):757-760.
[3] SCHNITZLER F,FIDDER H,FERRANTE M,et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease:results from a single-centre cohort[J]. Gut,2009,58(4):492-500. DOI:10.1136/gut.2008.155812.
[4] RICART E,PANACCIONE R,LOFTUS EV,et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic:the first 100 patients[J]. Am J Gastroenterol,2001,96(3):722-729.
[5] KONSTANTINOS P,CHEIFETZ AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy[J]. World J Gastroenterol,2017,23(34):6197-6200. DOI:10.3748/wjg.v23.i34.6197.
[6] 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2012年·广州)[J]. 中华内科杂志,2012,51(10):818-831.
[7] 刘占举. 英夫利西单抗治疗克罗恩病的作用机制[J]. 中华内科杂志,2013,52(12):1065-1067.
[8] SEMINERIO JL,LOFTUS EV JR,COLOMBEL JF,et al. Infliximab for Crohn's disease:the first 500 patients followed up through 2009[J]. Dig Dis Sci,2013,58(3):797-806. DOI:10.1007/s10620-012-2405-z.
[9] CAVIGLIA R,RIBOLSI M,RIZZI M,et al. Maintenance of remission with infliximab in inflammatory bowel disease:efficacy and safety long-term follow-up[J]. World J Gastroenterol,2007,13(39):5238-5244.
[10] 王智云,郑柳,张明红. 英夫利西单抗与硫唑嘌呤联用治疗克罗恩病临床疗效观察[J]. 实用临床医药杂志,2014,18(1):75-78.
[11] YARUR AJ,KANAGALA V,STEIN DJ,et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease[J]. Aliment Pharmacol Ther,2017,45(7):933-940. DOI:10.1111/apt.13970.
[12] WU XL,CHEN RP,TAO LP,et al. Infliximab combined with enteral nutrition for managing Crohn's disease complicated with intestinal fistulas[J]. Gastroenterol Res Pract,2016,2016:5947926.
[13] YANG BL,CHEN YG,GU YF,et al. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease[J]. World J Gastroenterol,2015,21(8):2475-2482. DOI:10.3748/wjg.v21.i8.2475.
[14] EHTESHAMI-AFSHAR S,NIKFAR S,REZAIE A,et al. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease[J]. Arch Med Sci,2011,7(6):1000-1012. DOI:10.5114/aoms.2011.26612.
[15] 刘爱玲,吕红,钱家鸣. 英夫利西单抗治疗炎症性肠病失应答[J]. 协和医学杂志,2015,6(2):140-145.
[16] STEENHOLDT C,PALARASAH Y,BENDTZEN K,et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease[J]. Aliment Pharmacol Ther,2013,37(12):1172-1183. DOI:10.1111/apt.12330.
[1] 左娜, 刘刚, 刘霄, 张彬柱, 刘中波, 王杨. 10例慢性难愈创面患者白细胞-富血小板纤维蛋白治疗的疗效分析[J]. 中国医科大学学报, 2018, 47(8): 748-750.
[2] 陶东霞,王璐,马兰,孙虹,王馨慧,顾莹,王实,侯丹丹. 臭氧自体血回输疗法治疗急性脑梗死的疗效分析[J]. 中国医科大学学报, 2017, 46(9): 860-861.
[3] 钟邦华,李昱骥,孔凡民. 直肠癌患者腹腔镜下全直肠系膜切除术疗效分析[J]. 中国医科大学学报, 2017, 46(8): 739-741.
[4] 曲航菲,周冬梅. 小儿脑瘫合并膝反张综合康复治疗及护理效果[J]. 中国医科大学学报, 2017, 46(5): 475-477.
[5] 康可歆 ,李昱骥. 载药胶束改善吉西他滨对胰腺癌的治疗效果[J]. 中国医科大学学报, 2017, 46(3): 281-283.
[6] 杨洋, 刘达. 电针刺激结合Bobath技术对脑卒中患者下肢运动功能障碍的疗效[J]. 中国医科大学学报, 2017, 46(12): 1087-1091.
[7] 袁梦, 韩琤波, 马洁韬, 黄乐天, 张树玲, 孙丽. 不可手术局部晚期非小细胞肺癌放化疗安全性及疗效分析[J]. 中国医科大学学报, 2017, 46(12): 1124-1128.
[8] 程慧,冯晓莹,徐华. 炎症性肠病242例临床分析[J]. 中国医科大学学报, 2017, 46(11): 1039-1041.
[9] 王臣,肖万军. 成年人股骨干骨折双钢板锁定内固定治疗的疗效分析[J]. 中国医科大学学报, 2017, 46(10): 924-926.
[10] 吴兵,刘晓伟,刘志. 氯解磷定不同用药方案对急性重度有机磷中毒的疗效比较[J]. 中国医科大学学报, 2017, 46(10): 949-951.
[11] 宋广德 ,李浩 ,牛洪欣 ,王传省 ,徐华. 吗啡皮下持续注射给药治疗中/重度癌痛患者的疗效分析[J]. 中国医科大学学报, 2016, 45(7): 661-663.
[12] 陈建康,朱鹏立,严瑜,潘晓莉,杨津,林帆,林春锦. 小剂量利伐沙班对预防2型糖尿病伴心房颤动高龄患者脑卒中的疗效分析[J]. 中国医科大学学报, 2015, 44(8): 755-757.
[13] 张新,周玉红,白云. 自体脂肪干细胞移植治疗2型糖尿病的安全性及有效性[J]. 中国医科大学学报, 2015, 44(12): 1137-1141.
[14] 张继倬,公兵,杨秀滨. 对比经皮冠状动脉介入治疗和小切口直接冠状动脉旁路移植术治疗前降支基底部狭窄的临床疗效的荟萃分析[J]. 中国医科大学学报, 2014, 43(5): 401-406.
[15] 贾长青,姚强,付勤. 人工颈椎间盘置换术的策略及潜在问题分析[J]. 中国医科大学学报, 2014, 43(12): 1100-1104.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA